

Linda Mileshtkin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/873945/publications.pdf>

Version: 2024-02-01

112
papers

7,409
citations

109321

35
h-index

58581

82
g-index

113
all docs

113
docs citations

113
times ranked

11098
citing authors

#	ARTICLE	IF	CITATIONS
1	Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2022, 33, 560-565.	2.5	4
2	Radiation Therapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of 3-Dimensional Conformal Radiation Therapy Versus Intensity-Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 390-399.	0.8	12
3	Pembrolizumab in Patients With Microsatellite Instabilityâ€“High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 752-761.	1.6	189
4	ENhancing Lifestyle Behaviors in Endometrial CancEr (ENABLE): A Pilot Randomized Controlled Trial. <i>Integrative Cancer Therapies</i> , 2022, 21, 153473542110698.	2.0	6
5	Treatment patterns after poly-ADP ribose polymerase (PARP) inhibitors in epithelial ovarian cancer patients. <i>International Journal of Gynecological Cancer</i> , 2022, , ijgc-2021-003009.	2.5	0
6	Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study. <i>Gynecologic Oncology</i> , 2022, 166, 211-218.	1.4	20
7	Cancer-of-Unknown-Primary-Origin: A SEERâ€“Medicare Study of Patterns of Care and Outcomes among Elderly Patients in Clinical Practice. <i>Cancers</i> , 2022, 14, 2905.	3.7	6
8	Uncertainty and the unmet informational needs of patients with cancer of unknown primary (CUP): a cross-sectional multi-site study. <i>Supportive Care in Cancer</i> , 2022, 30, 8217-8229.	2.2	4
9	FAPI PET/CT: Will It End the Hegemony of ¹⁸ F-FDG in Oncology?. <i>Journal of Nuclear Medicine</i> , 2021, 62, 296-302.	5.0	82
10	Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design. <i>Oncologist</i> , 2021, 26, e394-e402.	3.7	39
11	ICON 9â€“an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 134-138.	2.5	21
12	Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 975-986.	0.8	20
13	Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1212-1220.	6.3	47
14	Living with and beyond metastatic non-small cell lung cancer: the survivorship experience for people treated with immunotherapy or targeted therapy. <i>Journal of Cancer Survivorship</i> , 2021, 15, 392-397.	2.9	22
15	A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience. <i>Oncologist</i> , 2021, 26, e769-e779.	3.7	48
16	Cancer Diagnoses Following Abnormal Noninvasive Prenatal Testing: A Case Series, Literature Review, and Proposed Management Model. <i>JCO Precision Oncology</i> , 2021, 5, 1001-1012.	3.0	19
17	REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 161, 374-381.	1.4	17
18	Developing clinical indicators for oncology: the inaugural cancer care indicator set for the Australian Council on Healthcare Standards. <i>Medical Journal of Australia</i> , 2021, 214, 528-531.	1.7	2

#	ARTICLE	IF	CITATIONS
19	Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 620-631.	10.7	215
20	Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial. , 2021, 9, e002255.		61
21	Supporting cancer care clinicians to “hold”™ their patients during and beyond the COVID “19 pandemic: a role for reflective ethics discussions. <i>Internal Medicine Journal</i> , 2021, 51, 1143-1145.	0.8	4
22	Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial. , 2021, 9, e003156.		6
23	Impact of COVID-19 on cancer service delivery: results from an international survey of oncology clinicians. <i>ESMO Open</i> , 2020, 5, e001090.	4.5	18
24	First clinical study of a pegylated diabody ¹²⁴I-labeled PEG-AVP0458 in patients with tumor-associated glycoprotein 72 positive cancers. <i>Theranostics</i> , 2020, 10, 11404-11415.	10.0	13
25	Understanding and information needs of cancer patients regarding treatment“focused genomic testing: A systematic review. <i>Psycho-Oncology</i> , 2020, 29, 632-638.	2.3	13
26	Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial. <i>Lancet Oncology</i> , The, 2019, 20, 1306-1315.	10.7	87
27	Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1273-1285.	10.7	305
28	OVQUEST “ Life after the diagnosis and treatment of ovarian cancer - An international survey of symptoms and concerns in ovarian cancer survivors. <i>Gynecologic Oncology</i> , 2019, 155, 126-134.	1.4	26
29	PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors. <i>Gynecologic Oncology</i> , 2019, 154, 531-538.	1.4	49
30	Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial “ ANZGOG 0903. <i>Gynecologic Oncology</i> , 2019, 154, 29-37.	1.4	35
31	Multidisciplinary home-based rehabilitation in inoperable lung cancer: a randomised controlled trial. <i>Thorax</i> , 2019, 74, 787-796.	5.6	44
32	A randomised phase II trial to examine feasibility of standardised, early palliative (STEP) care for patients with advanced cancer and their families [ACTRN12617000534381]: a research protocol. <i>Pilot and Feasibility Studies</i> , 2019, 5, 44.	1.2	10
33	Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 1472-1478.	7.0	38
34	The trajectory of patients who die from metastatic prostate cancer: a population“based study. <i>BJU International</i> , 2019, 123, 19-26.	2.5	13
35	The Victorian Comprehensive Cancer Centre lung cancer clinical audit: collecting the UK National Lung Cancer Audit data from hospitals in Australia. <i>Internal Medicine Journal</i> , 2019, 49, 1001-1006.	0.8	0
36	Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion. <i>Journal of Clinical Investigation</i> , 2019, 129, 1940-1945.	8.2	37

#	ARTICLE	IF	CITATIONS
37	Transition Points for the Routine Integration of Palliative Care in Patients With Advanced Cancer. <i>Journal of Pain and Symptom Management</i> , 2018, 56, 185-194.	1.2	31
38	Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2018, 19, 295-309.	10.7	426
39	Survival difference according to mutation status in a prospective cohort study of Australian patients with metastatic non-small-cell lung carcinoma. <i>Internal Medicine Journal</i> , 2018, 48, 37-44.	0.8	12
40	Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 569-580.	7.0	79
41	Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. <i>European Journal of Cancer</i> , 2018, 105, 88-102.	2.8	53
42	Advancing clinical research globally: Cervical cancer research network from Mexico. <i>Gynecologic Oncology Reports</i> , 2018, 25, 90-93.	0.6	8
43	Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative. <i>Modern Pathology</i> , 2018, 31, 1851-1861.	5.5	35
44	Perceptions of cancer of unknown primary site: a national survey of Australian medical oncologists. <i>Internal Medicine Journal</i> , 2017, 47, 408-414.	0.8	9
45	Survey of practices around pharmaceutical company funding for continuing professional development among medical oncologists and trainees in Australia. <i>Internal Medicine Journal</i> , 2017, 47, 888-893.	0.8	8
46	Glut-1 expression in small cervical biopsies is prognostic in cervical cancers treated with chemoradiation. <i>Clinical and Translational Radiation Oncology</i> , 2017, 2, 53-58.	1.7	8
47	P2.07-008 Victorian Comprehensive Cancer Centre Lung Cancer Clinical Audit: Collecting the UK National Lung Cancer Audit data from hospitals in Australia. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1106-S1107.	1.1	0
48	Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. <i>Oncolmmunology</i> , 2017, 6, e1264565.	4.6	102
49	Differences in experiences of care between patients diagnosed with metastatic cancer of known and unknown primaries: mixed-method findings from the 2013 cancer patient experience survey in England. <i>BMJ Open</i> , 2017, 7, e017881.	1.9	29
50	Discussing and prescribing expensive unfunded anticancer drugs in Australia. <i>ESMO Open</i> , 2017, 2, e000170.	4.5	4
51	Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2017, 18, 1274-1284.	10.7	1,376
52	Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition. <i>Clinical Cancer Research</i> , 2017, 23, 1862-1874.	7.0	107
53	Impact of a specialist clinical cancer pharmacist at a multidisciplinary lung cancer clinic. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, e367-e374.	1.1	23
54	P331 Transition to Palliative Care for Patients with Metastatic Prostate Cancer: How Well Have We Integrated?. <i>Journal of Pain and Symptom Management</i> , 2016, 52, e150-e151.	1.2	1

#	ARTICLE	IF	CITATIONS
55	P332 Exploring the Landscape of Palliative Care for People with Non-Hodgkin's Lymphoma: Do They Receive Quality End-of-Life Care?. <i>Journal of Pain and Symptom Management</i> , 2016, 52, e151-e152.	1.2	0
56	PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer. <i>The Cochrane Library</i> , 2016, , .	2.8	1
57	A community-based model of rapid autopsy in end-stage cancer patients. <i>Nature Biotechnology</i> , 2016, 34, 1010-1014.	17.5	66
58	Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. <i>Lancet Oncology</i> , The, 2016, 17, 1386-1395.	10.7	357
59	Continuing variation and barriers to nurse-led vaginal dilator education for women with gynaecological cancer receiving radiotherapy. <i>European Journal of Oncology Nursing</i> , 2016, 24, 20-21.	2.1	4
60	Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1114-1126.	10.7	135
61	Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial. <i>British Journal of Cancer</i> , 2016, 115, 1179-1185.	6.4	19
62	Advances and Concepts in Cervical Cancer Trials: A Road Map for the Future. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 199-207.	2.5	32
63	Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer. <i>Modern Pathology</i> , 2016, 29, 174-181.	5.5	68
64	Nonsurgical Management of Cervical Cancer: Locally Advanced, Recurrent, and Metastatic Disease, Survivorship, and Beyond. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e299-e309.	3.8	21
65	Development and validation of a gene expression tumour classifier for cancer of unknown primary. <i>Pathology</i> , 2015, 47, 7-12.	0.6	35
66	Whole-genome characterization of chemoresistant ovarian cancer. <i>Nature</i> , 2015, 521, 489-494.	27.8	1,206
67	Geriatric assessment of older patients with cancer in Australia: A multicentre audit. <i>Journal of Geriatric Oncology</i> , 2015, 6, 185-193.	1.0	9
68	The Cervix Cancer Research Network: A Global Outreach Effort on Behalf of the Gynecologic Cancer InterGroup. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 506-508.	0.8	12
69	Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. <i>Modern Pathology</i> , 2015, 28, 836-844.	5.5	343
70	18F-FDG PET/CT following chemoradiation of uterine cervix cancer provides powerful prognostic stratification independent of HPV status: a prospective cohort of 105 women with mature survival data. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1825-1832.	6.4	21
71	Why We Need to Continue to Research Ways to Improve the Treatment of Locally Advanced Cervical Cancer. <i>Oncology & Hematology Review</i> , 2015, 11, 110.	0.2	1
72	Ultrasound guided conformal brachytherapy of cervix cancer: survival, patterns of failure, and late complications. <i>Journal of Gynecologic Oncology</i> , 2014, 25, 206.	2.2	62

#	ARTICLE	IF	CITATIONS
73	The survival outcome and patterns of failure in node positive endometrial cancer patients treated with surgery and adjuvant radiotherapy with curative intent. <i>Journal of Gynecologic Oncology</i> , 2014, 25, 313.	2.2	6
74	We should not settle for low-level evidence but should always use the best available evidence. <i>Journal of Gynecologic Oncology</i> , 2014, 25, 349.	2.2	1
75	Pertuzumab and Erlotinib in Patients With Relapsed Non-Small Cell Lung Cancer: A Phase II Study Using 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging. <i>Oncologist</i> , 2014, 19, 175-176.	3.7	21
76	Acceptability of Early Integration of Palliative Care in Patients with Incurable Lung Cancer. <i>Journal of Palliative Medicine</i> , 2014, 17, 553-558.	1.1	48
77	Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS). <i>Gynecologic Oncology</i> , 2014, 133, 16-22.	1.4	47
78	In Replay: Psychiatric Morbidity in Patients with Lung Cancer. <i>Chest</i> , 2014, 145, 666.	0.8	0
79	Patients Treated With Platinum-Doublet Chemotherapy for Advanced Non-Small-Cell Lung Cancer Have Inferior Outcomes If Previously Treated With Platinum-based Chemoradiation. <i>Clinical Lung Cancer</i> , 2013, 14, 508-512.	2.6	13
80	Resistance to CDK2 Inhibitors Is Associated with Selection of Polyploid Cells in <i>CCNE1</i> -Amplified Ovarian Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 5960-5971.	7.0	97
81	Suicide in Lung Cancer. <i>Chest</i> , 2013, 144, 1245-1252.	0.8	42
82	Early Cardiovascular Death in Patients with Cancer. <i>New England Journal of Medicine</i> , 2012, 367, 1572-1573.	27.0	2
83	Predictive Molecular Tumour Testing: What Are the Obstacles between Bench and Bedside?. <i>Chemotherapy Research and Practice</i> , 2012, 2012, 1-8.	1.6	3
84	What constitutes a multidisciplinary team meeting?. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2011, 7, 317-317.	1.1	1
85	Prospective, non-randomized phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinoma. <i>Gynecologic Oncology</i> , 2011, 120, 179-184.	1.4	12
86	Rational use of trastuzumab in metastatic and locally advanced breast cancer: Implications of recent research. <i>Breast</i> , 2011, 20, 101-110.	2.2	9
87	Patients' understanding of clinical trials needs to be assessed in the context of understanding of overall goals of care. <i>Supportive Care in Cancer</i> , 2011, 19, 1067-1068.	2.2	2
88	Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non-Small Cell Lung Cancer Treated with Erlotinib. <i>Clinical Cancer Research</i> , 2011, 17, 3304-3315.	7.0	126
89	A cost analysis of febrile neutropenia management in Australia: ambulatory v. in-hospital treatment. <i>Australian Health Review</i> , 2011, 35, 491.	1.1	20
90	Care requirements of patients with advanced cancer within a specialist centre "moving to person-centered approaches. <i>International Journal of Person Centered Medicine</i> , 2011, 1, 167-176.	0.2	2

#	ARTICLE	IF	CITATIONS
91	Access to expensive anti-cancer drugs. <i>Journal of Law & Medicine</i> , 2011, 19, 232-43.	0.0	1
92	What Should a Support Program for People with Lung Cancer Look Like? Differing Attitudes of Patients and Support Group Facilitators. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1227-1232.	1.1	24
93	The practical challenges of recruitment and retention when providing psychotherapy to advanced breast cancer patients. <i>Supportive Care in Cancer</i> , 2010, 18, 1605-1613.	2.2	10
94	Does Multidisciplinary Care Enhance the Management of Advanced Breast Cancer?: Evaluation of Advanced Breast Cancer Multidisciplinary Team Meetings. <i>Journal of Oncology Practice</i> , 2010, 6, 294-300.	2.5	41
95	TP53 Mutations In Relapsed/Refractory Multiple Myeloma (MM) Treated with Thalidomide (Thal) or Thalidomide Combination Therapy. <i>Blood</i> , 2010, 116, 4046-4046.	1.4	0
96	To Tell or Not to Tell: The Community Wants to Know About Expensive Anticancer Drugs As a Potential Treatment Option. <i>Journal of Clinical Oncology</i> , 2009, 27, 5830-5837.	1.6	24
97	Discussing Expensive Anticancer Drugs. <i>Journal of Clinical Oncology</i> , 2009, 27, 476-477.	1.6	5
98	Predicting durable remissions following thalidomide therapy for relapsed myeloma. <i>Leukemia and Lymphoma</i> , 2009, 50, 223-229.	1.3	9
99	Lung cancer: Challenges and solutions for supportive care intervention research. <i>Palliative and Supportive Care</i> , 2008, 6, 281-287.	1.0	62
100	Treatment Strategies in Elderly Patients with Multiple Myeloma. <i>Drugs and Aging</i> , 2007, 24, 829-850.	2.7	4
101	An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2007, 48, 46-55.	1.3	50
102	Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines, angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome. <i>Haematologica</i> , 2007, 92, 1075-1082.	3.5	36
103	Prolonged Progression Free Survival Does Not Relate to Quality of Response to Treatment with Thalidomide in Patients with Relapsed Multiple Myeloma (MM).. <i>Blood</i> , 2007, 110, 2718-2718.	1.4	8
104	The troublesome toxicity of peripheral neuropathy with thalidomide. <i>Leukemia and Lymphoma</i> , 2006, 47, 2276-2279.	1.3	28
105	Development of Neuropathy in Patients With Myeloma Treated With Thalidomide: Patterns of Occurrence and the Role of Electrophysiologic Monitoring. <i>Journal of Clinical Oncology</i> , 2006, 24, 4507-4514.	1.6	195
106	A Multicenter Phase II Trial of Thalidomide and Celecoxib for Patients with Relapsed and Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2005, 11, 5504-5514.	7.0	50
107	The adverse prognostic impact of advanced age in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2005, 46, 951-966.	1.3	31
108	Tracking Dendritic Cells In Vivo in Patients with Multiple Myeloma.. <i>Blood</i> , 2005, 106, 3469-3469.	1.4	0

#	ARTICLE	IF	CITATIONS
109	In Vivo Tracking of Macrophage Activated Killer Cells to Sites of Metastatic Ovarian Carcinoma.. Blood, 2005, 106, 3874-3874.	1.4	2
110	Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide. British Journal of Haematology, 2003, 123, 747-748.	2.5	5
111	Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood, 2003, 102, 69-77.	1.4	129
112	CNS Listeriosis Confused With Leptomeningeal Carcinomatosis in a Patient With a Malignant Insulinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2002, 25, 576-579.	1.3	8